Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015))

Min Hee Ryu; Changhoon Yoo; Jong Gwang Kim; Baek Yeol Ryoo; Young Soo Park; Sook Ryun Park; Hye Suk Han; Ik Joo Chung; Eun Kee Song; Kyung Hee Lee; Seok Yun Kang; Yoon Koo Kang

doi:10.1016/j.ejca.2021.01.019

Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015))

Min Hee Ryu
, Changhoon Yoo
, Jong Gwang Kim
, Baek Yeol Ryoo
, Young Soo Park
, Sook Ryun Park
, Hye Suk Han
, Ik Joo Chung
, Eun Kee Song
, Kyung Hee Lee
, Seok Yun Kang
, Yoon Koo Kang^*

^*Corresponding author for this work

Department of Medicine

University of Ulsan
Kyungpook National University
Chungbuk National University
Chonnam National University
Yeungnam University
Ajou University

Research output: Contribution to journal › Comment/debate

Abstract

The authors regret that the dosage details for trastuzumab in the original publication were incorrectly given as 8 and 6 mg/m². The correct dosage for trastuzumab should be 8 and 6 mg/kg. The online article has been updated accordingly. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	187
Number of pages	1
Journal	European Journal of Cancer
Volume	147
DOIs	https://doi.org/10.1016/j.ejca.2021.01.019
State	Published - 2021.04

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Quacquarelli Symonds(QS) Subject Topics

Medicine
Biological Sciences

Access to Document

10.1016/j.ejca.2021.01.019

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015))'. Together they form a unique fingerprint.

Cite this

Ryu, M. H., Yoo, C., Kim, J. G., Ryoo, B. Y., Park, Y. S., Park, S. R., Han, H. S., Chung, I. J., Song, E. K., Lee, K. H., Kang, S. Y., & Kang, Y. K. (2021). Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015)). European Journal of Cancer, 147, 187. https://doi.org/10.1016/j.ejca.2021.01.019

Ryu, Min Hee ; Yoo, Changhoon ; Kim, Jong Gwang et al. / Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015)). In: European Journal of Cancer. 2021 ; Vol. 147. pp. 187.

@article{7e53ec3e6c5746cba6e6e03af81a52be,

title = "Corrigendum to {\textquoteleft}Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer{\textquoteright}, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015))",

abstract = "The authors regret that the dosage details for trastuzumab in the original publication were incorrectly given as 8 and 6 mg/m2. The correct dosage for trastuzumab should be 8 and 6 mg/kg. The online article has been updated accordingly. The authors would like to apologise for any inconvenience caused.",

author = "Ryu, \{Min Hee\} and Changhoon Yoo and Kim, \{Jong Gwang\} and Ryoo, \{Baek Yeol\} and Park, \{Young Soo\} and Park, \{Sook Ryun\} and Han, \{Hye Suk\} and Chung, \{Ik Joo\} and Song, \{Eun Kee\} and Lee, \{Kyung Hee\} and Kang, \{Seok Yun\} and Kang, \{Yoon Koo\}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = apr,

doi = "10.1016/j.ejca.2021.01.019",

language = "English",

volume = "147",

pages = "187",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Ryu, MH, Yoo, C, Kim, JG, Ryoo, BY, Park, YS, Park, SR, Han, HS, Chung, IJ, Song, EK, Lee, KH, Kang, SY & Kang, YK 2021, 'Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015))', European Journal of Cancer, vol. 147, pp. 187. https://doi.org/10.1016/j.ejca.2021.01.019

Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015)). / Ryu, Min Hee; Yoo, Changhoon; Kim, Jong Gwang et al.
In: European Journal of Cancer, Vol. 147, 04.2021, p. 187.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015))

AU - Ryu, Min Hee

AU - Yoo, Changhoon

AU - Kim, Jong Gwang

AU - Ryoo, Baek Yeol

AU - Park, Young Soo

AU - Park, Sook Ryun

AU - Han, Hye Suk

AU - Chung, Ik Joo

AU - Song, Eun Kee

AU - Lee, Kyung Hee

AU - Kang, Seok Yun

AU - Kang, Yoon Koo

PY - 2021/4

Y1 - 2021/4

N2 - The authors regret that the dosage details for trastuzumab in the original publication were incorrectly given as 8 and 6 mg/m2. The correct dosage for trastuzumab should be 8 and 6 mg/kg. The online article has been updated accordingly. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that the dosage details for trastuzumab in the original publication were incorrectly given as 8 and 6 mg/m2. The correct dosage for trastuzumab should be 8 and 6 mg/kg. The online article has been updated accordingly. The authors would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85101249937

U2 - 10.1016/j.ejca.2021.01.019

DO - 10.1016/j.ejca.2021.01.019

M3 - Comment/debate

C2 - 33612368

AN - SCOPUS:85101249937

SN - 0959-8049

VL - 147

SP - 187

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR et al. Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015)). European Journal of Cancer. 2021 Apr;147:187. doi: 10.1016/j.ejca.2021.01.019

Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015))

Abstract

UN SDGs

Quacquarelli Symonds(QS) Subject Topics

Access to Document

Other files and links

Fingerprint

Cite this